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Background: Two stimulant medications, modafinil and d -amphetamine, when tested
individually, have shown safety and efficacy for treatment of cocaine addiction. We hypoth-
esized that the combination of modafinil and d -amphetamine, at low doses, would show
equivalent or greater benefit in reducing cocaine use compared to higher doses of each indi-
vidual medication or placebo. Methods: Sixteen week, randomized, parallel-group design
with four treatment arms comparing placebo to modafinil 400 mg; d -amphetamine 60 mg;
modafinil 200 mg plus d -amphetamine 30 mg. Primary outcome variables, retention and
cocaine use, were analyzed on the sample of 73 participants who received the first dose of
the study medication. Results: Retention rates did not differ between groups and were gen-
erally low, with 40% remaining in treatment at week 12 and 20% at week 16. Participants
receiving the combination of modafinil and d -amphetamine showed a trend of increased
cocaine use over time with a corresponding low Bayesian probability of benefit (33%). Rel-
atively better cocaine outcomes were observed in the placebo and d -amphetamine only
groups.The study medications were generally well-tolerated with few adverse effects, yet
rates of adherence were suboptimal (≤80%). Conclusion: Data from this preliminary inves-
tigation fail to provide evidential support for conducting a larger study of this dual-agonist
medication combination for treatment of cocaine dependence.
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INTRODUCTION
A number of candidate stimulant-like agents have been studied for
the treatment of cocaine dependence based on the “agonist sub-
stitution” model, similar to the use of methadone to treat opiate
dependence. By definition, an agonist-like medication should pos-
sess neurochemical and behavioral effects similar to those of the
abused drug, with diminished abuse liability (Herin et al., 2010).
Given the key role of dopamine in the acute and chronic effects of
cocaine, drugs that interact with this monoamine neurotransmit-
ter have been prime targets for medication development research
(Moeller et al., 2008). Medications enhancing dopaminergic func-
tion that have been examined with promising results include, e.g.,
bupropion, disulfiram, methylphenidate, levodopa, methamphet-
amine (Margolin et al., 1995; Grabowski et al., 1997; Petrakis et al.,
2000; Carroll et al., 2004; Poling et al., 2006; Schmitz et al., 2008;
Mooney et al., 2009).
Two stimulant medications, modafinil and d-amphetamine,
when tested individually, have shown some evidence of safety and
benefit for cocaine addiction. Consistent with its ability to weakly
inhibit DA reuptake, the behavioral effects of modafinil overlap
to some extent with those of prototypical stimulants, including
enhanced extracellular DA in the nucleus accumbens (Ferraro
et al., 1996; Madras et al., 2006). In two early clinical trials, cocaine
dependent subjects receiving modafinil were more likely to sub-
mit cocaine-negative urine samples than subjects receiving placebo
(Dackis et al., 2005). More recently, Anderson et al. (2009) found
a significant effect of modafinil that increased weekly percentage
of cocaine non-use days in the subgroup of cocaine dependent
patients without comorbid alcohol dependence, but not in the
total sample. d-Amphetamine enhances dopaminergic function-
ing via reversal of the dopamine transporter, and has been tested
in three placebo-controlled trials. Two studies by the same group
(Grabowski et al., 2001, 2004) reported a reduction in cocaine-
positive urine drug screens in cocaine dependent individuals
treated with sustained-release d-amphetamine up to 60 mg/day
compared with placebo-treated individuals. One of these stud-
ies used dual-diagnosis cocaine-opiate – dependent individuals
also being treated with methadone (Grabowski et al., 2004).
Shearer et al. (2003) conducted a controlled community trial
with a heterogeneous population of cocaine users in which oral
immediate-release d-amphetamine was administered. Whereas
outcomes favored the treatment group in terms of cocaine use
measured by urinalysis and self-report, improvements were not
statistically significant in this small sample (N = 30) pilot study.
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Longo et al. (2010) reported d-amphetamine produced enhanced
retention and decreased illicit use in a methamphetamine abusing
population. These reports, along with multiple community clinic
and case series reports of reductions in amphetamine abuse during
d-amphetamine maintenance, point to potential utility.
Thus, agonist-like medications for cocaine and methampheta-
mine dependence have been examined in several studies though
the results are not consistent and further large randomized trials
are required. New strategies have been recommended, including
use of agonist combinations (Shearer, 2008; Herin et al., 2010).
The use of modafinil with d-amphetamine as a treatment strat-
egy is based on the rationale that the combination should more
adequately provide “substitution” or “replacement” of depleted
brain monoamines. Each agent enhances dopaminergic transmis-
sion, though via different mechanisms, potentially resulting in
broader actions that target also the norepinephrine, glutamate,
and other systems modulated by cocaine. Given the documented
safety and tolerability of each agent at low doses, the likelihood
of side effect or adverse events is low and offset by the likelihood
of incremental benefit expected from the combination. For this
preliminary investigation, we tested the hypothesis that the low
dose combination of modafinil (200 mg/day) and d-amphetamine
(30 mg/day) would produce greater benefit in reducing cocaine




This double-blind, placebo-controlled randomized clinical trial
compared 400 mg of modafinil to 60 mg of sustained-release d-
amphetamine to the combination of 200 mg modafinil and 30 mg
of d-amphetamine in a sample of 73 subjects with cocaine depen-
dence. Following assignment to one of the four treatment groups,
subjects attended thrice weekly clinic visits, weekly individual
therapy, and received study medication for 16 weeks. Following
a 2-week intake evaluation phase, baseline information was used
to urn randomize subjects to ensure balanced groups with respect
to gender and severity of cocaine addiction (Stout et al., 1994).
Treatment began with a 1-week dose escalation schedule, described
below, followed by maintenance for 16 weeks, and a 1-week dose
reduction at week 17.
SUBJECTS
All participants were enrolled at the outpatient Treatment Research
Clinic (TRC) located at the Center for Neurobehavioral Research
on Addictions in Houston, Texas. Inclusion required being
between 18 and 55 years old and meeting Diagnostic and Statisti-
cal Manual of Mental Disorders-IV (DSM-IV) criteria for current
cocaine dependence with provision of at least one benzoylec-
gonine (BE)-positive urine during the intake evaluation period
prior to randomization. Exclusion criteria included: (1) depen-
dence on alcohol or drugs other than cannabis or nicotine; (2)
current non-substance induced Axis I psychotic, depressive, or
anxiety disorder; (3) presence of existing cardiovascular disease
as determined by EKG evaluated by the collaborating cardiologist
(AED), and/or symptoms suggestive of cardiovascular problems
not related to drug use such as hypertension (treated or untreated),
stroke, chest pain; (4) taking medications that would contraindi-
cate study medications (e.g., MAO inhibitors, tricyclic antidepres-
sants, SSRI’s); (5) pregnancy or nursing; and (6) court-mandated
treatment for cocaine dependence.
The TRC conducts an initial eligibility screening on all indi-
viduals who call in response to ads for various treatment studies
(Sayre et al., 2004). Those who qualify are further screened for one
of several ongoing clinical trials. Of the 84 subjects who were deter-
mined as being eligible to participate in the current trial, 11 did not
return for their study start visit and were thus lost to follow-up,
leaving a total of 73 subjects in the randomized, intent-to-treat,
sample.
The research protocol, consent form, and all assess-
ment/advertising materials were reviewed and approved by the
Committee for the Protection of Human Subjects (CPHS) of the
University of Texas Medical School, Houston (Clinicaltrials.gov
Identifier: NCT00218062).
ASSESSMENTS
Psychiatric diagnostic and addiction severity information were
collected at intake using the Structured Clinical Interview for
DSM-IV (Spitzer and First, 2005) and the Addiction Severity Index
(McLellan et al., 1992). Prior to starting medication, all subjects
underwent a medical history and physical examination, laboratory
tests (liver and thyroid function), and cardiac evaluation (i.e., 12-
lead electrocardiogram). Vital signs (including heart rate, blood
pressure, and weight) were obtained weekly during treatment.
EKG’s were conducted at the time of screening and repeated every
4 weeks during treatment. Blood pressure was closely monitored
throughout the study, with a requirement of being normotensive
(<140/90) to receive study medications. A side-effects checklist
was completed each week, with moderate to severely rated items
evaluated by the study nurse and reviewed by the study physi-
cian (FGM). Medication compliance was assessed via fluorescent
tests for riboflavin detection in urine samples (see below) and
by self-reported number of pills taken each day, as measured
using a written Timeline Followback (TLFB) method. Cocaine
use was assessed via urinalysis results detecting the presence of
BE (≥300 mg/ml) and by self-reported cocaine use as recorded on
the TLFB.
TREATMENTS
During the 16-weeks of outpatient treatment, participants took
three capsules daily (two in the morning, one in the afternoon).
All active and placebo capsules were identical in appearance and
each contained 50 mg riboflavin for subsequent evaluation of
medication compliance (Del Boca et al., 1996). Medication admin-
istration was initiated during a 5-day run-up period. Modafinil
started at 200 mg (day 1) and increased to 400 mg (days 2–5).
d-Amphetamine SR (Dexedrine Spansules) started at 15 mg (day
1–2), increased to 30 mg (day 3; 15 mg, BID), 45 mg (day 4; 15 mg,
TID), and 60 mg (day 5; 15 mg bid plus 30 mg qd). For the combi-
nation condition, dosages of modafinil and d-amphetamine were
escalated to one-half of that for the single medication conditions.
A 5-day dose reduction schedule occurred at week 17. All investi-
gators and staff, except the pharmacist, were blind to medication
assignment.
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Manual-based, cognitive-behavioral therapy was provided
for 1 h each week by master’s-level therapists. The cognitive-
behavioral therapy emphasized relapse prevention and coping
skills (for a full description see Schmitz et al., 2001).
DATA ANALYTIC PLAN
Primary outcome variables, retention, and cocaine use, were ana-
lyzed on the sample of participants who were randomized to
treatment and received the first dose of the study medication.
Demographic and baseline characteristics of study participants
by group were compared using analysis of variance (ANOVA)
and Fisher’s exact test for continuous and categorical variables,
respectively. For retention, group differences in the percentage
of subjects remaining in treatment over the 16-week study were
tested using Kaplan–Meier survival analysis. The primary out-
come of cocaine use was examined using urine toxicology results.
Treatment differences in weekly fraction of cocaine-positive urines
were compared using generalized linear mixed models (GLMM)
for repeated measures analysis including terms for treatment, time,
and treatment by time interaction. The primary null hypothesis,
that there was no difference between medication groups in primary
outcome measures, was tested using the traditional Frequentist
approach at a 5% level of statistical significance. Significant inter-
actions were followed by post hoc tests of the simple effects of
time within each treatment to determine if differences were dri-
ven by greater change in the combination group relative to other
treatment groups. We then applied exploratory Bayesian analyses
to add interpretive statements regarding the probability that the
alternative hypothesis exists, i.e., that treatment conferred benefit
given the observed data, expressed as the probability that the odds
ratio for each simple effect was less than 1.0.
Whereas the classical frequentist approach constructs a rejec-
tion region and reports the probability that the null hypothesis
obtains, based on an all or nothing dichotomy (p≤ 0.05), the
Bayesian approach constructs prior and posterior distributions
to quantify the probability of each hypothesis (null and alter-
native), given observed data. Together, these two complementary
approaches can provide a more accurate parameter estimate when
the sample size is small (for a full description, see Bayarri and
Berger, 2004; Green et al., 2009).
RESULTS
SAMPLE CHARACTERISTICS
The demographic and substance use characteristics of partici-
pants at randomization are presented in Table 1. The mostly
male (85%), African American (64%) sample had a mean age of
42 years (SD= 8.1), a mean education level of 13 years (SD= 1.7),
and a reported unemployment rate of 60%. Recent cocaine use
was reported to be 17.9 (SD= 8.5) days in the past 30, with
lifetime cocaine use reported to be 13.6 (SD= 7.7) years. The
treatment groups were not significantly different on these baseline
characteristics.
RETENTION IN TREATMENT
Rates of retention during treatment did not differ between groups,
log rankχ2 (1)= 1.307, p= 0.72, and were generally low, with 40%
remaining in treatment at week 12 and 20% at week 16. Overall
median number of days in treatment was 52 (95% C.I. 28–84).
COCAINE USE
Frequentist analyses modeled cocaine-positive urines using linear
and quadratic temporal trends, the main effects of treatment, and
the interaction of the linear trend and treatment (Figure 1). A sta-
tistically reliable time by treatment interaction, F (3, 921)= 2.93,
p= 0.03, indicated differential change over time as a function
of treatment condition. Simple effects of time within each treat-
ment condition suggested that, for the placebo group, the odds of
having a cocaine-positive urine decreased significantly for every
additional day in treatment (OR= 0.980, 95% CI 0.973–0.987).
As shown in Table 2, Bayesian estimates produced similar results,










N % N % N % N %
Male 21 95.5 16 84.2 11 73.3 14 87.5
White 6 27.3 6 31.6 3 20.0 2 12.5
Black 15 68.2 12 63.2 10 66.7 10 62.5
Hispanic 1 4.6 1 5.3 2 13.3 3 18.8
Employment (unemployed) 16 72.7 13 68.4 10 71.4 5 31.3
Mean SD Mean SD Mean SD Mean SD
Age 44.3 6.5 42.6 8.3 41.2 8.5 41.9 9.0
Education (years) 12.7 1.6 12.9 1.5 13.2 2.0 13.5 1.8
Cocaine use (past 30 days) 17.1 8.8 16.4 8.6 20.5 7.3 17.7 9.6
Lifetime cocaine (years) 12.9 8.1 12.4 7.5 13.9 8.0 15.5 7.4
Alcohol use (past 30 days) 10.6 10.8 10.8 9.9 6.4 9.0 10.1 8.5
Lifetime alcohol (years) 20.5 11.3 17.8 11.4 16.5 13.9 19.5 12.9
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FIGURE 1 | Probability of cocaine use by medication condition and time.
Table 2 | Frequentist and Bayesian results for the simple effects of time within each treatment condition on cocaine-positive urines.
Effect Frequentist results Bayesian results
Estimate 95% CI T (df), p-value Estimate 95% CBI P (O.R.<1|Data)
d -Amphetamine 0.987 0.966–1.008 −1.22 (323), p≤0.223 0.987 0.943–1.023 0.772
Modafinil 1.007 0.993–1.022 1.03 (244), p≤0.302 1.008 0.994–1.022 0.140
Modafinil+d -amphetamine 1.004 0.985–1.023 0.40 (184), p≤0.692 1.012 0.946–1.074 0.330
Placebo 0.980 0.973–0.987 −6.09 (10), p≤0.0001 0.979 0.958–0.998 0.985
CBI, Bayesian 95% credible interval.
while offering the alternative interpretation of there being a 98.5%
chance that placebo conferred benefit (i.e., OR <1) in reduc-
ing the probability of cocaine-positive urines, given the current
data. A similar trend of decreased cocaine use over time with
a corresponding high Bayesian probability of benefit (77.2%)
was found in the d-amphetamine only group. For the condi-
tions of modafinil+ d-amphetamine and modafinil only, the non-
significant simple effects of time suggested increased cocaine use
and were supported by corresponding low Bayesian probabilities
of benefit (i.e., OR’s<1), 14.0 and 33.0%, respectively.
SIDE-EFFECTS, ADVERSE EVENTS, COMPLIANCE
Items most frequently endorsed on the weekly side-effects check-
list are listed in Table 3. Participants in the d-amphetamine only
group reported more symptoms throughout the study than the
other groups; endorsing items suggestive of stimulant-like effects,
e.g., increased energy, anxiety, and changes in sleep. Six study-
related adverse events occurred: three involving cardiac-related
symptoms (e.g., chest pain, change in EKG) in participants receiv-
ing combined modafinil and d-amphetamine group (N = 1),
modafinil only (N = 1), and d-amphetamine only (N = 1). In
two cases of reported chest pain, the study medication was dis-
continued and subjects were sent for cardiology evaluation at
the nearby emergency clinic. Both subjects returned to the clinic
within 3 days with no further symptoms. In the case of the EKG,
non-specific ST-T wave changes at week 3 were reviewed by cardi-
ology to rule out the possibility of new injury or ischemia. Study
medication (modafinil+ d-amphetamine) was discontinued. The
subject returned to the clinic 1 week later, reporting no cardiovas-
cular symptoms and showing improvement on repeat EKG. The
other three events included pneumonia (modafinil), migraine
(modafinil), and constipation (modafinil+ d-amphetamine). All
of these events were reviewed and approved by the IRB and Data
Safety Monitoring Board. Medication adherence rates based on
two measures: (1) self-reported days in which “all” study med-
ications were taken; and (2) riboflavin-positive urines, were in
the moderate range and not different across groups: combined
modafinil and d-amphetamine group (65.8; 76.8%), modafinil
only (64.5; 70%), d-amphetamine only (80.2; 67.1%), and placebo
(73.2; 66.7%).
DISCUSSION
This study found no evidence that the dual-agonist combination of
modafinil and d-amphetamine had benefit over individual stim-
ulant medications or placebo in the treatment of cocaine depen-
dence. Participants receiving the medication combination showed
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Table 3 | Items most frequently endorsed on the weekly side-effects checklist.
Item d -Amphetamine Modafinil Modafinil+d -amphetamine Placebo Total
Increase energy 22 10 5 9 46
Changes in sleep patterns 14 6 5 10 35
Anxiety or tension 10 9 6 8 33
Change in sexual performance or desire 16 5 6 6 33
Problems concentrating 12 4 7 7 30
a trend of increased cocaine use over time with a corresponding
low Bayesian probability of benefit (33%). Relatively better cocaine
outcomes were observed in the placebo and d-amphetamine only
groups. The study medications were generally well-tolerated with
few adverse effects, yet rates of medication adherence were less
than optimal.
Of the many pharmacological strategies that have been inves-
tigated for cocaine dependence, those that “work” presumably
via restoration of extracellular dopamine levels have shown effi-
cacy for reducing drug use compared with placebo. Two such
medications, each showing initial positive outcomes, dextroam-
phetamine (Grabowski et al., 2001, 2004) and modafinil (Dackis
et al., 2005; Anderson et al., 2009), but each having differ-
ent dopamine-enhancing mechanisms, were expected to produce
more powerful treatment effects when given in combination.
Our negative results, however, call into question the adequacy
of this medication combination. The lower dose of each agent
was combined in this preliminary investigation, leaving open the
possibility that more robust actions and effects require higher
doses. In general, data from previous studies indicate greater effec-
tiveness of agonist medication when dosing at the high end of
the recommended range, including 60 mg/day or higher of d-
amphetamine (Grabowski et al., 2001, 2004). Higher doses of
stimulant medications may be especially appropriate for patients
with more severe stimulant dependence (Herin et al., 2010), as in
the present sample. Whereas our pharmacological objective was
to enhance dopamine; others have argued for using stimulant
medications having broader actions on additional systems (e.g.,
5-HT, NE) known to be involved in the neurochemical effects
of cocaine (Rothman et al., 2001). Ideally being able to predict
response to agonist treatment based on underlying biological tone
would prove useful in medication matching (Elkashef and Vocci,
2003).
This study employed a longer duration of treatment (16 weeks),
based on preliminary findings suggesting a delay in the onset of
maximum treatment effects for d-amphetamine (Grabowski et al.,
2001). In hindsight, it is clear that extending treatment should be
accompanied by methods to enhance retention. High attrition,
especially beyond week 12, was a major limitation of this prelimi-
nary study. Incentive-based strategies have been shown to increase
visit attendance substantially (Businelle et al., 2009; Schmitz et al.,
2010). Such strategies have also been effective for enhancing med-
ication compliance (Schmitz et al., 2010) which was also less than
optimal in the current study. To the extent that pill-taking burden
in this study, i.e., three capsules daily, contributed to medication
non-compliance, it is advisable for future medication trials to con-
sider newer amphetamine formulations that have slower onset and
longer-lasting efficacy (e.g., lisdexamfetamine: NCT00958282).
We opted to test this novel medication combination in a small
number of subjects first to obtain evidence of efficacy and safety
before designing a larger confirmatory study. Preliminary studies
like this, however, have limitations, including unavoidable low sta-
tistical power and unreliable estimates. To address this uncertainty,
we included Bayesian probability distributions that are not affected
by sample size and can provide more quantitative conclusions
regarding the probable magnitude of effects (Gurrin et al., 2000).
In addition to “accepting” the null hypothesis based on conven-
tional non-significant results (p< 0.05), Bayesian results informed
us of only a 33% probability that treatment with combination of
modafinil and d-amphetamine reduced cocaine-positive urines,
given the current data. Thus, we can conclude with reasonable
confidence that there is very little evidential support for conduct-
ing a larger study of this medication combination for treatment of
cocaine dependence.
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